Published in AIDS Weekly, March 10th, 1997
But early intervention with therapies including protease inhibitors may prevent this untimely aging.
CD8+ T cells attack viral infections by secreting soluble antiviral factors and by killing virus-infected cells directly.
Long-term nonprogressors enrolled in the MACS study - a longitudinal study of a large cohort of men who have sex with men - retain intact CD8+ lymphocyte responses. Most of the HIV+ MACS participants, however,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1997-03-10)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.